Participants 141 154 4
subgroups wit
Participants 156 191 4
glucocorticoid-induced osteoporosis
Participants 305 365 3
different subgroups with glucocorticoid-induced osteoporosis
Participants 580 607 4
patients on glucocorticoids
Participants 869 877 6
Patients
Participants 1083 1292 6
e subgrouped by age; gender; menopausal status in women; dose and duration of prednisone during the trial; and baseline serum 25-OH vitamin D, LS BMD T-score, creatinine clearance, and concomitant medication u
Participants 1874 1895 3
MD. Osteoporotic pati
